THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,725 | -17.9% | 13,989 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $147,042 | -7.4% | 14,207 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $158,844 | -12.5% | 14,640 | -9.5% | 0.00% | -50.0% |
| Q4 2022 | $181,472 | +15.6% | 16,174 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $157,000 | +15.4% | 15,513 | +3.6% | 0.00% | +100.0% |
| Q2 2022 | $136,000 | -4.9% | 14,979 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $143,000 | -12.8% | 14,941 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $164,000 | +50.5% | 14,831 | +0.9% | 0.00% | 0.0% |
| Q3 2021 | $109,000 | -38.4% | 14,705 | +20.8% | 0.00% | 0.0% |
| Q2 2021 | $177,000 | -33.5% | 12,174 | -6.6% | 0.00% | -50.0% |
| Q1 2021 | $266,000 | +16.2% | 13,038 | +1.1% | 0.00% | 0.0% |
| Q4 2020 | $229,000 | +16.2% | 12,894 | -3.2% | 0.00% | 0.0% |
| Q3 2020 | $197,000 | -4.8% | 13,325 | +34.9% | 0.00% | -33.3% |
| Q2 2020 | $207,000 | -10.4% | 9,878 | -1.2% | 0.00% | -25.0% |
| Q1 2020 | $231,000 | – | 9,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $78,677,176 | 13.94% |
| Irenic Capital Management LP | 1,700,937 | $19,084,513 | 9.15% |
| Weiss Asset Management LP | 7,457,060 | $83,668,213 | 3.41% |
| Newtyn Management, LLC | 1,450,000 | $16,269,000 | 3.36% |
| Palliser Capital (UK) Ltd | 97,100 | $1,089,462 | 2.65% |
| Chescapmanager LLC | 850,988 | $9,548 | 2.24% |
| Park West Asset Management LLC | 1,920,324 | $21,546,035 | 2.11% |
| Baupost Group | 11,419,226 | $128,124 | 2.09% |
| Saturn V Capital Management LP | 141,339 | $1,334,342 | 1.11% |
| Oasis Management Co Ltd. | 296,960 | $3,331,891 | 0.66% |